MCID: VLV011
MIFTS: 50

Vulvovaginal Candidiasis

Categories: Infectious diseases, Reproductive diseases

Aliases & Classifications for Vulvovaginal Candidiasis

MalaCards integrated aliases for Vulvovaginal Candidiasis:

Name: Vulvovaginal Candidiasis 12 3 15 17
Candidiasis of Vulva and Vagina 12 33
Candidiasis, Vulvovaginal 44 72
Candidiasis Vulvovaginal 55
Candidal Vulvovaginitis 12
Monilial Vulvovaginitis 12
Candidal: Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2272
ICD9CM 35 112.1
MeSH 44 D002181
NCIt 50 C2914
SNOMED-CT 68 72605008
ICD10 33 B37.3
UMLS 72 C0700345

Summaries for Vulvovaginal Candidiasis

CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems. Sometimes Candida can multiply and cause an infection if the environment inside the vagina changes in a way that encourages its growth. Candidiasis in the vagina is commonly called a "vaginal yeast infection." Other names for this infection are "vaginal candidiasis," "vulvovaginal candidiasis," or "candidal vaginitis."

MalaCards based summary : Vulvovaginal Candidiasis, also known as candidiasis of vulva and vagina, is related to candidiasis and bacterial vaginosis. An important gene associated with Vulvovaginal Candidiasis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and NF-kappaB Signaling. The drugs Miconazole and Dequalinium have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and cervix, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A candidiasis that involves fungal infection of the vaginal mucous membranes in women caused by Candida albicans. The symptoms include intense vulval pruritus, burning, erythema and dyspareunia associated with a creamy white, curd-like discharge.

Wikipedia : 75 Vaginal yeast infection, also known as candidal vulvovaginitis and vaginal thrush, is excessive growth... more...

Related Diseases for Vulvovaginal Candidiasis

Diseases related to Vulvovaginal Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Related Disease Score Top Affiliating Genes
1 candidiasis 32.6 MBL2 DEFB4A CLEC7A
2 bacterial vaginosis 31.4 TLR2 MBL2 DEFB4A
3 oral candidiasis 31.1 DEFB4A DEFB1
4 vulvar vestibulitis syndrome 31.0 NLRP3 MBL2
5 immunoglobulin alpha deficiency 30.9 MBL2 CD79A
6 cervicitis 30.6 IL2 DEFB4A
7 immune deficiency disease 30.1 IL4 IL2 CD79A
8 exanthem 30.0 NLRP3 IL2
9 skin disease 29.8 IL4 DEFB4A CD79A
10 bacterial infectious disease 29.7 TLR2 MBL2 DEFB4A DEFB1
11 vaginitis 11.0
12 vulvovaginitis 10.9
13 candida glabrata 10.8
14 vaginal discharge 10.8
15 immunoglobulin g deficiency 10.6 MBL2 CD79A
16 coccidioidomycosis 10.6 MBL2 CLEC7A
17 corneal abscess 10.5 DEFB4A DEFB1
18 osteonecrosis of the jaw 10.5 DEFB4A DEFB1
19 overgrowth syndrome 10.5
20 clonorchiasis 10.4 IL2 CD79A
21 prosthetic joint infection 10.4 TLR2 MBL2
22 trichomoniasis 10.4
23 trichomonas vaginalis trichomoniasis 10.4
24 fungal keratitis 10.4 TLR2 CLEC7A
25 tularemia 10.4 TLR2 MBL2
26 haemophilus influenzae 10.4 TLR2 CLEC7A
27 neisseria meningitidis infection 10.4 TLR2 MBL2
28 localized scleroderma 10.3 DEFB4A DEFB1
29 hematopoietic stem cell transplantation 10.3 IL2 CLEC7A
30 ige responsiveness, atopic 10.3
31 congenital hypogammaglobulinemia 10.3 IL4 CD79A
32 mycobacterium kansasii 10.3 TLR2 NLRP3
33 septic arthritis 10.3 TLR2 DEFB4A
34 amyotrophic lateral sclerosis 3 10.3
35 immunodeficiency with hyper-igm, type 1 10.3 IL4 CD79A
36 chromoblastomycosis 10.3 IL4 CLEC7A
37 orofacial granulomatosis 10.2 IL4 CD79A
38 rheumatic fever 10.2 MBL2 IL2
39 wells syndrome 10.2 NLRP3 IL2
40 allergic bronchopulmonary aspergillosis 10.2 MBL2 IL4
41 milk allergy 10.2 IL4 CD79A
42 folliculitis 10.2 IL4 DEFB4A
43 human immunodeficiency virus type 1 10.2
44 deficiency anemia 10.2
45 diarrhea 10.2
46 acquired immunodeficiency syndrome 10.2
47 cytokine deficiency 10.2
48 cryptococcosis 10.2 MBL2 IL4
49 virus associated hemophagocytic syndrome 10.2 IL4 IL2
50 autoimmune vasculitis 10.2 IL4 IL2

Comorbidity relations with Vulvovaginal Candidiasis via Phenotypic Disease Network (PDN): (show all 12)


Acute Cystitis Anxiety
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hypertension, Essential
Hypothyroidism Oral Candidiasis
Osteoporosis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Vulvovaginal Candidiasis:



Diseases related to Vulvovaginal Candidiasis

Symptoms & Phenotypes for Vulvovaginal Candidiasis

MGI Mouse Phenotypes related to Vulvovaginal Candidiasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 CD101 CD79A CLEC7A F2 IL2 IL4
2 homeostasis/metabolism MP:0005376 9.86 CD79A CLEC7A F2 IL2 IL4 MBL2
3 digestive/alimentary MP:0005381 9.85 CLEC7A F2 IL2 IL4 NLRP3 TLR2
4 immune system MP:0005387 9.81 CD101 CD79A CLEC7A F2 IL2 IL4
5 liver/biliary system MP:0005370 9.35 CD79A IL2 IL4 NLRP3 TLR2
6 renal/urinary system MP:0005367 9.02 CD79A IL4 MBL2 NLRP3 TLR2

Drugs & Therapeutics for Vulvovaginal Candidiasis

Drugs for Vulvovaginal Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Dequalinium Approved, Investigational Phase 4 6707-58-0
3
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
6 Antifungal Agents Phase 4
7 14-alpha Demethylase Inhibitors Phase 4
8 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
9 Cytochrome P-450 Enzyme Inhibitors Phase 4
10 Steroid Synthesis Inhibitors Phase 4
11 Hormone Antagonists Phase 4
12 Anti-Infective Agents Phase 4
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
14 Cytochrome P-450 CYP2C19 Inhibitors Phase 4
15
Metronidazole Approved Phase 3 443-48-1 4173
16
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
17
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029
18
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
19
Secnidazole Approved Phase 3 3366-95-8
20
Terconazole Approved Phase 3 67915-31-5 441383
21
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
22 Antiparasitic Agents Phase 3
23 Anti-Bacterial Agents Phase 3
24 Antiprotozoal Agents Phase 3
25 Liposomal amphotericin B Phase 3
26 Clindamycin palmitate Phase 3
27 Clindamycin phosphate Phase 3
28 Alkylating Agents Phase 3
29 Cytochrome P-450 CYP3A Inhibitors Phase 3
30
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
31
Titanium dioxide Approved Phase 2 13463-67-7
32
Metformin Approved Phase 2 657-24-9 4091 14219
33
Canagliflozin Approved Phase 2 842133-18-0
34 Immunologic Factors Phase 1, Phase 2
35 Vaccines Phase 1, Phase 2
36 Rezafungin Phase 2
37 Gastrointestinal Agents Phase 1, Phase 2
38 Antacids Phase 1, Phase 2
39 Adjuvants, Immunologic Phase 1, Phase 2
40 Anti-Ulcer Agents Phase 1, Phase 2
41 Dipeptidyl-Peptidase IV Inhibitors Phase 2
42 Sitagliptin Phosphate Phase 2
43 Sodium-Glucose Transporter 2 Inhibitors Phase 2
44 HIV Protease Inhibitors Phase 2
45 Incretins Phase 2
46
protease inhibitors Phase 2
47 Hypoglycemic Agents Phase 2
48 Anti-Obesity Agents Phase 2
49 Acidophilus Phase 1
50
Butoconazole Approved 64872-77-1, 64872-76-0 47472

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis. Completed NCT02248506 Phase 4
2 Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
3 An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
4 A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
5 Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE Completed NCT00194324 Phase 4 Miconazole nitrate
6 A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis Completed NCT00000951 Phase 4 Fluconazole
7 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
8 A Multicenter Open-label Non-comparative Study Of Fluconazole For The Treatment Of Vulvovaginal Candidiasis. Completed NCT01806623 Phase 3 Fluconazole
9 Diabetes Mellitus and Vulvovaginal Candidiasis: Prevalence of Infection and Its Rationale Management Completed NCT00353561 Phase 3 Boric;Fluconazole
10 An Investigator-blinded, Active-controlled Phase 3 Study to Prove the Non-inferior Efficacy of a Clotrimazole Ovule (500 mg) Versus a Clotrimazole Vaginal Tablet (500 mg) in Vaginal Candidiasis Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
11 A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001 Completed NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
12 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis. International Phase III, Randomised, Multi-centre, Parallel-group, Two Arm, Double-blind Superiority Trial Versus Placebo. Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
13 A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
14 Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge. Bogotá D. C. Colombia. Completed NCT02111629 Phase 3 Fluconazole and Secnidazole
15 A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
16 Randomized Clinical Trial for Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Recruiting NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
17 A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules Versus Fluconazole and Placebo in the Treatment of Acute Vulvovaginal Candidiasis Episodes in Subjects With Recurrent Vulvovaginal Candidiasis Recruiting NCT03840616 Phase 3 VT-1161 150 mg capsule;Fluconazole 150 mg
18 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis Recruiting NCT03562156 Phase 3 VT-1161;Placebo
19 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis Recruiting NCT03561701 Phase 3 VT-1161;Placebo
20 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Recruiting NCT03734991 Phase 3 Ibrexafungerp;Placebo
21 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (AVVC). Recruiting NCT03987620 Phase 3 Ibrexafungerp;Placebo
22 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) Not yet recruiting NCT04029116 Phase 3 Fluconazole Tablet;IBREXAFUNGERP;Placebo oral tablet
23 Ketoconazole In Situ Gel Versus Terconazole Cream for Treatment of Vaginal Candidiasis Not yet recruiting NCT03473418 Phase 3 Ketoconazole;Terconazole
24 Comparative Study of the Efficacy and Safety of LactiSal 1% Vaginal Gel and LactSal 50 mg Vaginal Tablet Versus Clotrimazole 100 mg Vaginal Tablet in the Treatment of Vulvovaginal Candidiasis (VVC) Withdrawn NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
25 Multi-center, Randomized, Placebo-controlled, Parallel-group, Double-blinded Study to Compare the Therapeutic Efficacy, Safety, and Tolerability of 3 Single Vaginal Doses of Arasertaconazole Nitrate Pessaries in the Treatment of VVC Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
26 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis Completed NCT02267382 Phase 2 VT-1161;Placebo
27 A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis Completed NCT01891331 Phase 2 VT-1161;Fluconazole
28 A Phase 2, Multicenter, Randomized, Active-controlled Study of the Safety and Tolerability of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis Completed NCT02733432 Phase 2 CD101 Vaginal Gel (3%);CD101 External gel (1%);CD101 Vaginal Ointment (6%);CD101 External ointment (1%);Fluconazole
29 A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Fluconazole Versus Fluconazole And MGCD290 for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
30 A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Dose-Finding Study to Compare the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03253094 Phase 2 Fluconazole;SCY-078
31 Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
32 A Multicenter, Randomized, Evaluator Blinded, Active-Controlled Study to Evaluate the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
33 A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
34 A Randomized Single Blind Safety and Efficacy Study of TOL-463 Vaginal Gel or Insert in the Treatment of Vaginitis (BV and/or VVC) Completed NCT02866227 Phase 2 TOL-463;TOL-463
35 A Double-Blind, Randomized Trial of Monthly Treatment With Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories Versus Placebo for Preventing Vaginal Infections in HIV-seronegative Women Completed NCT01230814 Phase 2 Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate);Placebo
36 A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference Arm Completed NCT00642278 Phase 2 Canagliflozin (JNJ-28431754);Sitagliptin;Placebo
37 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-28431754 in Nondiabetic Overweight and Obese Subjects Completed NCT00650806 Phase 2 Canagliflozin (JNJ-28431754);Placebo
38 Randomized Clinical Trial of a Mucoadhesive Gel Containing EPP-AF in Patients Diagnosed With Vulvovaginal Candidiasis Recruiting NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
39 A Randomized, Double-Blind, Placebo-Controlled Trial Of TOL-463 Insert for Suppression Of Bacterial Vaginosis (BV) Not yet recruiting NCT03930745 Phase 2 TOL-463
40 A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Withdrawn NCT03167957 Phase 2 Oral Encochleated Amphotericin B (CAMB);Oral Encochleated Amphotericin B (CAMB)
41 A Double-Blind,Randomized Placebo-Controlled Study Using Probiotic Lactobacillus GR-1 and RC-14 as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status NCT00479947 Phase 1 Probiotics (Natural product);Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
42 A Phase I Randomized Placebo Controlled Study of a Virosome Formulated Anti-Candida Vaccine (PEV7) Administered by the Vaginal (PEV7C) or Intramuscular (PEV7B) Route to Healthy Adult Volunteers Completed NCT01067131 Phase 1
43 Study Evaluating the Optimal Dosage for Equivalence Between a Tablet and Capsule Dosage Form of an Intravaginal Treatment With Total Freeze-dried Culture of Lcr Regenerans® (Lactobacillus Rhamnosus Lcr35®) on Vaginal Flora Colonisation in Healthy Women. Completed NCT02730494 Phase 1
44 A Two Part Randomized, Open-Label Phase I Safety and Pharmacokinetic Evaluation of Gel and Ovule Formulations of TOL-463 (Intravaginal Therapy) in 18-45 Year Old Healthy Female Subjects and Women With Vaginitis Completed NCT01812889 Phase 1 TOL-463 Vaginal ovule;TOL-463 Vaginal gel
45 Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial Unknown status NCT03075046
46 "A Comparison Study of the WaterWorks® Douching Device vs. Commercial OTC Douching Device for the Reduction or Abatement of Perceived Vaginal Odor With or Without Complaints of Discharge in Women With no Infectious Causes of Vaginitis" Unknown status NCT00417365
47 Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis Unknown status NCT02185456 Early Phase 1 750 mg metronidazole/ 200 mg miconazole vaginal suppository;Standard of care
48 A Randomized Study Evaluating the Therapeutic Equivalence and Safety of Butoconazole Nitrate Vaginal Cream, 2% and Gynazole 1 (Butoconazole Nitrate) Vaginal Cream, 2%, Against a Vehicle Control in the Treatment of Vulvovaginal Candidiasis Completed NCT01039584 Butoconazole Nitrate Vaginal Cream;Placebo;Gynazole 1 vaginal cream
49 A Non-Interventional Extension Study to Investigate Vulvovaginal Candidiasis Recurrence and Candida Colonization Following a Phase 2 Randomized, Active-Controlled Study of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis Completed NCT02888197
50 A Multi-center, Randomized, Investigator-blinded, Parallel-group Study, Designed to Evaluate the Safety and Clinical Equivalence of Terconazole Vaginal Suppositories, 80 mg (Test Product) and Terconazole Vaginal Suppositories, 80 mg (Reference Product) in the Treatment of Vulvovaginal Candidiasis Caused by Candida Species Completed NCT00803738 Terconazole Vaginal Suppository;Terazol Vaginal Suppository

Search NIH Clinical Center for Vulvovaginal Candidiasis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


butoconazole
Butoconazole
Butoconazole nitrate
Clotrimazole
Fluconazole
Fluconazole
Gentian Violet
Itraconazole
Itraconazole
Ketoconazole
Miconazole
Miconazole Nitrate
MICONAZOLE NITRATE PWDR
NYSTATIN PWDR
Sulfanilamide
terconazole
Terconazole
tioconazole
Tioconazole

Cochrane evidence based reviews: candidiasis, vulvovaginal

Genetic Tests for Vulvovaginal Candidiasis

Anatomical Context for Vulvovaginal Candidiasis

MalaCards organs/tissues related to Vulvovaginal Candidiasis:

41
Testes, Skin, Cervix, Colon, Neutrophil, B Cells, T Cells

Publications for Vulvovaginal Candidiasis

Articles related to Vulvovaginal Candidiasis:

(show top 50) (show all 1091)
# Title Authors PMID Year
1
Mannan-binding lectin in women with a history of recurrent vulvovaginal candidiasis. 9 38
19910100 2010
2
Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. 9 38
18715406 2008
3
MBL2 genetic screening in patients with recurrent vaginal infections. 9 38
18211540 2008
4
Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. 9 38
17470593 2007
5
Mannose-binding lectin and vulvovaginal candidiasis. 9 38
16256117 2006
6
Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. 9 38
15825027 2005
7
Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. 9 38
12942410 2003
8
Longitudinal trajectory of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis during pregnancy as well as the impact on pregnancy outcomes: a preliminary study. 38
29685081 2019
9
Biodegradable cross-linked chitosan nanoparticles improve anti-Candida and anti-biofilm activity of TistH, a peptide identified in the venom gland of the Tityus stigmurus scorpion. 38
31349502 2019
10
Influence of recurrent vulvovaginal candidiasis on quality of life issues. 38
31270690 2019
11
Questions remain regarding the presence of fungal species biofilm in women with vulvovaginal candidiasis. 38
31029662 2019
12
Epidemiology and antifungal susceptibility patterns of Candida isolates from Greek women with vulvovaginal candidiasis. 38
31132175 2019
13
Estimated Burden of Fungal Infections in Namibia. 38
31426392 2019
14
A comparative analysis of protein virulence factors released via extracellular vesicles in two Candida albicans strains cultivated in a nutrient-limited medium. 38
31412284 2019
15
Impaired Th17 cell proliferation and decreased pro-inflammatory cytokine production in CXCR3/CXCR4 double-deficient mice of vulvovaginal candidiasis. 38
30656691 2019
16
Combined systemic (fluconazole) and topical (metronidazole + clotrimazole) therapy for a new approach to the treatment and prophylaxis of recurrent candidiasis. 38
31106557 2019
17
Should we absolutely reject the hypothesis that epithelium-based Candida biofilms contribute to the pathogenesis of human vulvovaginal candidiasis? 38
31283906 2019
18
Candida albicans vaginitis in a murine model is reduced by polypeptide-enriched Gastrodia elata extracts. 38
31373210 2019
19
Reactional changes in short-term levonorgestrel-releasing intrauterine system (lng-ius) use. 38
31340317 2019
20
Molecular diagnosis of vaginitis: comparing qPCR and microbiome profiling approaches to current microscopy scoring. 38
31315951 2019
21
The classic azole antifungal drugs are highly potent endocrine disruptors in vitro inhibiting steroidogenic CYP enzymes at concentrations lower than therapeutic Cmax. 38
31330226 2019
22
Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. 38
31299136 2019
23
The Burden of Serious Fungal Infections in Tajikistan. 38
31330914 2019
24
The Burden of Serious Fungal Infections in Kyrgyzstan. 38
31331088 2019
25
Probiotics for oral and vulvovaginal candidiasis: A review. 38
31112355 2019
26
CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial. 38
30893271 2019
27
Vaginal microbiota of asymptomatic bacterial vaginosis and vulvovaginal candidiasis: Are they different from normal microbiota? 38
31212037 2019
28
Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China. 38
30968320 2019
29
Recurrent vulvo-vaginal candidiasis in Abidjan (Côte d'Ivoire): Aetiology and associated factors. 38
31010729 2019
30
A systems genomics approach identifies SIGLEC15 as a susceptibility factor in recurrent vulvovaginal candidiasis. 38
31189718 2019
31
Study on the prevalence and factors associated to vulvodynia in Spain. 38
31260857 2019
32
Targeted point-of-care testing compared with syndromic management of urogenital infections in women (WISH): a cross-sectional screening and diagnostic accuracy study. 38
31031172 2019
33
Hormones modulate Candida vaginal isolates biofilm formation and decrease their susceptibility to azoles and hydrogen peroxide. 38
31254346 2019
34
Virulence and antifungal susceptibility of microsatellite genotypes of Candida albicans from superficial and deep locations. 38
31037772 2019
35
Antifungal activity of analogues of antimicrobial peptides isolated from bee venoms against vulvovaginal Candida spp. 38
30753486 2019
36
Accuracy of the BD MAX™ vaginal panel in the diagnosis of infectious vaginitis. 38
30685805 2019
37
A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis. 38
30885896 2019
38
Vaginal lactobacilli inhibit growth and hyphae formation of Candida albicans. 38
31148560 2019
39
Intravaginal Delivery of Syngonanthus nitens (Bong.) Ruhland Fraction Based on a Nanoemulsion System Applied to Vulvovaginal Candidiasis Treatment. 38
30890237 2019
40
Estimated Burden of Serious Fungal Infections in Ghana. 38
31083531 2019
41
Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol. 38
31122991 2019
42
[Changes of local vaginal immune regulation in rats infected with vulvovaginal candidiasis]. 38
31154715 2019
43
Multilocus sequence typing analysis of Candida africana from vulvovaginal candidiasis. 38
31117966 2019
44
Therapeutic effectiveness of type I interferon in vulvovaginal candidiasis. 38
31158491 2019
45
Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation. 38
30945022 2019
46
Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis. 38
29846682 2019
47
Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment. 38
30565745 2019
48
Comparing the effectiveness of Salvia officinalis, clotrimazole and their combination on vulvovaginal candidiasis: A randomized, controlled clinical trial. 38
30663184 2019
49
NDV-3A vaccination prevents C. albicans colonization of jugular vein catheters in mice. 38
30996274 2019
50
Candida glabrata Fungemia Following Robotic Total Laparoscopic Hysterectomy and Bilateral Salpingo-oophorectomy in a Patient with Recurrent Vulvovaginitis: A Case Report. 38
31187014 2019

Variations for Vulvovaginal Candidiasis

Expression for Vulvovaginal Candidiasis

Search GEO for disease gene expression data for Vulvovaginal Candidiasis.

Pathways for Vulvovaginal Candidiasis

Pathways related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 TLR2 NLRP3 MBL2 IL4 IL2 DEFB4A
2 12.07 TLR2 IL4 IL2 CD79A
3
Show member pathways
12.06 TLR2 DEFB4A DEFB1
4
Show member pathways
12.05 IL4 IL2 F2
5
Show member pathways
12.03 TLR2 IL4 DEFB4A
6
Show member pathways
11.87 NLRP3 IL2 CLEC7A
7
Show member pathways
11.83 TLR2 IL4 DEFB4A
8 11.76 TLR2 MBL2 CLEC7A
9
Show member pathways
11.64 TLR2 IL4 F2
10 11.56 IL4 IL2 CD79A
11 11.23 IL4 IL2 CD101
12 11.03 IL4 IL2
13 10.96 IL4 IL2
14 10.89 IL4 IL2
15 10.53 TLR2 NLRP3 F2

GO Terms for Vulvovaginal Candidiasis

Cellular components related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 MBL2 IL4 IL2 F2 DEFB4A DEFB1
2 extracellular region GO:0005576 9.5 NLRP3 MBL2 IL4 IL2 F2 DEFB4A
3 Golgi lumen GO:0005796 8.8 F2 DEFB4A DEFB1

Biological processes related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.72 TLR2 NLRP3 MBL2 DEFB1 CLEC7A
2 defense response to bacterium GO:0042742 9.71 MBL2 DEFB4A DEFB1
3 immune response GO:0006955 9.65 TLR2 IL4 IL2 DEFB4A DEFB1
4 defense response GO:0006952 9.63 NLRP3 DEFB4A DEFB1
5 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.54 F2 DEFB4A DEFB1
6 positive regulation of B cell proliferation GO:0030890 9.52 IL4 IL2
7 acute-phase response GO:0006953 9.51 MBL2 F2
8 B cell activation GO:0042113 9.49 IL4 CD79A
9 positive regulation of T cell differentiation GO:0045582 9.48 IL4 IL2
10 positive regulation of isotype switching to IgG isotypes GO:0048304 9.43 IL4 IL2
11 immune system process GO:0002376 9.43 TLR2 NLRP3 MBL2 IL2 CLEC7A CD79A
12 positive regulation of interleukin-13 production GO:0032736 9.4 NLRP3 IL4
13 cytokine secretion involved in immune response GO:0002374 9.16 TLR2 NLRP3
14 defense response to Gram-positive bacterium GO:0050830 9.02 TLR2 NLRP3 MBL2 DEFB4A DEFB1

Molecular functions related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.5 MBL2 IL2 CLEC7A
2 growth factor activity GO:0008083 9.43 IL4 IL2 F2
3 lipopolysaccharide binding GO:0001530 9.37 TLR2 F2
4 peptidoglycan binding GO:0042834 9.16 TLR2 NLRP3
5 signaling pattern recognition receptor activity GO:0008329 8.96 TLR2 CLEC7A
6 CCR6 chemokine receptor binding GO:0031731 8.62 DEFB4A DEFB1

Sources for Vulvovaginal Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....